Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
NCT04676529
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelofibrosis
Interventions
DRUG:
PXS-5505
Sponsor
Syntara